Akari prices $2.5M registered direct offering of ADSs and warrants at $0.80/unit

Akari Therapeutics Plc

Issued 3,125,000 ADSs (each representing 2,000 ordinary shares) and Series E/F warrants to purchase up to 3,125,000 ADSs each, all at $0.80 per unit.
Gross proceeds expected ~$2.5M; closing on or about Oct 16, 2025.
Warrants exercisable at $0.98 per ADS upon shareholder approval; 5-year term for Series E, 30-month for Series F.
Net proceeds for working capital, general corporate purposes, and R&D on novel ADC payload.
Placement agent Ladenburg Thalmann receives 7.2% fee plus warrants for 125,000 ADSs at $1.00.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.